The role of non-corticosteroid related factors in osteonecrosis (ON) in systemic lupus erythematosus: A nested case-control study of inception patients

Lupus

Volumn 16, Issue 3, 2007, Pages 157-162

  Prasad, R ^a   Ibanez, D ^a   Gladman, D ^a   Urowitz, M B ^a,b  

^a UNIVERSITY OF TORONTO   (Canada)

^b TORONTO WESTERN HOSPITAL   (Canada)

Author keywords

Corticosteroids; Lupus; Osteonecrosis; Risk factors

Indexed keywords

ACETYLSALICYLIC ACID; AZATHIOPRINE; CHLOROQUINE; CORTICOSTEROID; CYCLOPHOSPHAMIDE; HYDROXYCHLOROQUINE; METHOTREXATE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PREDNISONE; STEROID;

ADOLESCENT; ADULT; ARTICLE; BONE NECROSIS; CASE CONTROL STUDY; CHILD; CLINICAL ASSESSMENT; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORTICOSTEROID INDUCED MYOPATHY; CORTICOSTEROID THERAPY; CUSHINGOID SYNDROME; DEMOGRAPHY; DISEASE COURSE; DISEASE PREDISPOSITION; DRUG DOSE COMPARISON; FEMALE; HUMAN; HYPERTENSION; LABORATORY TEST; MAJOR CLINICAL STUDY; MALE; MULTIVARIATE ANALYSIS; PRIORITY JOURNAL; PSYCHOSIS; RISK FACTOR; SPINE INJURY; SYSTEMIC LUPUS ERYTHEMATOSUS; TREATMENT DURATION; TREATMENT RESPONSE; UNSPECIFIED SIDE EFFECT; VERTEBRA COLLAPSE;

ADMINISTRATION, ORAL; ADRENAL CORTEX HORMONES; ADULT; ARTHROGRAPHY; CASE-CONTROL STUDIES; COHORT STUDIES; FEMALE; HUMANS; LUPUS ERYTHEMATOSUS, SYSTEMIC; MALE; MULTIVARIATE ANALYSIS; OSTEONECROSIS; RISK FACTORS;

EID: 33947723461     PISSN: 09612033     EISSN: None     Source Type: Journal    
DOI: 10.1177/0961203306075771     Document Type: Article

References (33)

1. Abu-Shakra M, Buskila D, Shoenfeld Y. Osteonecrosis in patients with SLE. Clinical Reviews in Allergy & Immunology 2003; 25: 13-24.
2. Assouline-Dayan Y, Chang C, Greenspan A, Shoenfeld Y, Gershwin ME. Pathogenesis and natural history of osteonecrosis. Seminars Arthritis Rheum 2002; 32: 94-124.
3. Dubois EL, Cozen L. Avascular (aseptic) bone necrosis associated with systemic lupus erythematosus. JAMA 1960; 174: 966-971.
4. Gladman DD, Urowitz MB, Chaudhry-Ahluwalia V, Hallet DC, Cook RJ. Predictive factors for symptomatic osteonecrosis in patients with systemic lupus erythematosus. J Rheumatol 2001; 28: 761-765.
5. Gladman DD, Goldsmith CH, Urowitz MB et al. The Systemic Lupus International Collaborating Clinics/American College of Rheumatology (SLICC/ACR) Damage Index for Systemic Lupus Erythematosus International Comparison. J Rheumatol 2000; 27: 373-376.
6. Gladman DD, Chaudhry-Ahluwalia V, Ibanez D, Bogoch E, Urowitz MB. Outcomes of symptomatic osteonecrosis in 95 patients with systemic lupus erythematosus. J Rheumatol 2001; 28: 2226-2229.
7. Abeles M, Urman JD, Rothfield NF. Aseptic necrosis of bone in systemic lupus erythematosus. Relationship to corticosteroid therapy. Arch Int Med 1978; 138: 750-754.
8. Migliaresi S, Picillo U, Ambrosone L et al. Avascular osteonecrosis in patients with SLE: relation to corticosteroid therapy and anticardiolipin antibodies. Lupus 1994; 3: 37-41.
9. Mok CC, Lau CS, Wong RW. Risk factors for avascular bone necrosis in systemic lupus erythematosus. Br J Rheumatol 1998; 37: 895-900.
10. Mont MA, Glueck CJ, Pacheco IH, Wang P, Hungerford DS, Petri M. Risk factors for osteonecrosis in systemic lupus erythematosus. J Rheumatol 1997; 24: 654-662.
11. Nagasawa K, Ishii Y, Mayumi T et al. Avascular necrosis of bone in systemic lupus erythematosus: possible role of haemostatic abnormalities. Ann Rheumatic Dis 1989; 48: 672-676.
12. Weiner ES, Abeles M. Aseptic necrosis and glucocorticosteroids in systemic lupus erythematosus: a reevaluation. J Rheumatol 1989; 16: 604-608.
13. Zizic TM, Marcoux C, Hungerford DS, Dansereau JV, Stevens MB. Corticosteroid therapy associated with ischemic necrosis of bone in systemic lupus erythematosus. Am J Med 1985; 79: 596-604.
14. Assouline-Dayan Y, Chang C, Greenspan A, Shoenfeld Y, Gershwin ME. Pathogenesis and natural history of osteonecrosis. Seminars Arthritis Rheum 2002; 32: 94-124.
15. Leventhal GH, Dorfman HD. Aseptic necrosis of bone in systemic lupus erythematosus. Seminars Arthritis Rheum 1974; 4: 73-93.
16. Tan EM, Cohen AS, Fries JF et al. The 1982 revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum 1982; 25: 1271-1277.
17. Hochberg MC. Updating the American College of Rheumatology revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum 1997; 40(Suppl 9):1725.
18. Gladman DD, Ibanez D, Urowitz MB. Systemic lupus erythematosus disease activity index 2000. J Rheumatol 2002; 29: 288-291.
19. Ibanez D, Urowitz MB, Gladman DD. Summarizing disease features over time I: Adjusted mean SLEDAI derivation and application to an index of disease Activity in lupus. J Rheumatol 2003; 30: 1977-1982.
20. Gladman D, Ginzler E, Goldsmith C et al. The development and initial validation of the Systemic Lupus International Collaborating Clinics/American College of Rheumatology damage index for systemic lupus erythematosus. Arthritis Rheum 1996; 39: 363-369.
21. Gladman DD, Goldsmith CH, Urowitz MB et al. The Systemic Lupus International Collaborating Clinics/American College of Rheumatology (SLICC/ACR) Damage Index for Systemic Lupus Erythematosus International Comparison. J Rheumatol 2000; 27: 373-376.
22. Chaudhry-Ahlawalia V, Gladman DD, Urowitz MB, Bogoch E, Farewell VT. Radiographic reports in osteonecrosis of the hip in systemic lupus erythematosus. Clinical Orth Rel Res 1998; 352: 131-136.
23. Klipper AR, Stevens MB, Zizic TM, Hungerford DS. Ischemic necrosis of bone in systemic lupus erythematosus. Medicine 1976; 55: 251-257.
24. Asherson RA, Liote F, Page B et al. Avascular necrosis of bone and antiphospholipid antibodies in systemic lupus erythematosus. J Rheumatol 1993; 20: 284-288.
25. Tektonidou MG, Malagari K, Vlachoyiannopoulos PG, Kelekis DA. Moutsopoulos HM. Asymptomatic avascular necrosis in patients with primary antiphospholipid syndrome in the absence of corticosteroid use: a prospective study by magnetic resonance imaging. Arthritis Rheum 2003; 48: 732-736.
26. Weiner ES, Abeles M. Aseptic necrosis and glucocorticosteroids in systemic lupus erythematosus: a reevaluation. J Rheumatol 1989; 16: 604-608.
27. Rascu A, Manger K, Kraetsch HG, Kalden IR, Manger B. Osteonecrosis in systemic lupus erythematosus, steroid-induced or a lupus-dependent manifestation? Lupus 1996; 5: 323-327.
28. Alarcon-Segovia D, Deleze M, Oria CV et al. Antiphospholipid antibodies and the antiphospholipid syndrome in systemic lupus erythematosus. A prospective analysis of 500 consecutive patients. Medicine 1989; 68: 353-365.
29. Houssiau FA, N'Zeusseu TA, Depresseux G et al. Magnetic resonance imaging-detected avascular osteonecrosis in systemic lupus erythematosus: lack of correlation with antiphospholipid antibodies. Br J Rheumatol 1998; 37: 448-453.
30. Mok MY, Farewell VT, Isenberg DA. Risk factors for avascular necrosis of bone in patients with systemic lupus erythematosus: is there a role for antiphospholipid antibodies? Ann Rheum Dis 2000; 59: 462-467.
31. Oinuma K, Harada Y, Nawata Y et al. Osteonecrosis in patients with systemic lupus erythematosus develops very early after starting high dose corticosteroid treatment. Ann Rheum Dis 2001; 60: 1145-1148.
32. Felson DT, Anderson JJ. Across-study evaluation of association between steroiddose and bolus steroids and avascular necrosis of bone. Lancet 1987; 1: 902-906.
33. Ibañez D, Gladman DD, Urowitz MB. Adjusted mean SLEDAI (AMS) is a predictor of outcome in SLE. J Rheumatol 2005; 32: 824-827.